Zalicus Inc. (ZLCS)
-NasdaqCM 0.59 
0.00(0.25%) May 24, 3:59PM EDT
| Prev Close: | 0.59 |
|---|
| Open: | 0.60 |
|---|
| Bid: | 0.37 x 100 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 1.69 |
|---|
| Beta: | 2.57 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 0.58 - 0.61 |
|---|
| 52wk Range: | 0.43 - 1.62 |
|---|
| Volume: | 227,348 |
|---|
| Avg Vol (3m): | 579,812 |
|---|
| Market Cap: | 74.84M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.32 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Zalicus Awaiting Data On Potential New Pain Medicationat Seeking Alpha(Thu, May 23)
- ZALICUS INC. FinancialsEDGAR Online Financials(Fri, May 17)
- Zalicus Presents Data on Novel, Oral, N- and T-Type Calcium Channel Blockers for the Treatment of PainBusiness Wire(Fri, May 10)
- ZALICUS INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Fri, May 10)
- Zalicus Secures New $25 Million Funding Commitment from Lincoln Park CapitalBusiness Wire(Wed, May 8)
- ZALICUS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and ExhibitsEDGAR Online(Wed, May 8)
- ZALICUS INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 3)
- Watching Zalicus Like A Hawkat Seeking Alpha(Thu, May 2)
- 2 Biotechs Primed For Prosperity In 2013at Seeking Alpha(Thu, May 2)
- Zalicus Reports Financial Results for the First Quarter 2013Business Wire(Thu, May 2)
- ZALICUS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Thu, May 2)
- ZALICUS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and ExhibitsEDGAR Online(Wed, May 1)
- ZALICUS INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; TranEDGAR Online(Fri, Apr 19)
- ZALICUS INC. Files SEC form 8-K, Change in Directors or Principal OfficersEDGAR Online(Thu, Apr 11)
- For Zalicus The Renewal Of Its Partnership With Novartis Will Be Vital For FY '13 Revenuesat Seeking Alpha(Wed, Apr 3)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 5.40 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.26 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.07 |
|---|
| Mean Recommendation*: | 2.2 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Zalicus Inc., a biopharmaceutical company, engages in the discovery and development of novel treatments for patients suffering from pain. The company develops Z160, a novel oral N-type calcium channel blocker that is under 2 Phase 2a clinical tria...
View More